Black, D.M., Schwartz, A.V., Ensrud, K.E., et al. (2006) Effects of Continuing or Stopping Alendronate after 5 Years of Treatment. The Fracture Intervention Trial Long-Term Extension (FLEX): A Randomized Trial. JAMA, 296, 2927-2938.
https://doi.org/10.1001/jama.296.24.2927

has been cited by the following article:

• TITLE: Bisphosphonates Zoledronate and Alendronate for the Management of Postmenopausal Osteoporosis

  AUTHORS: IsraaIsraa Ahmed Radwan, Nahed Sedky Korany, Bassant Adel Ezzat

  KEYWORDS: Bisphosphonates, Alendronate, Zoledronate, Postmenopausal Osteoporosis

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.7 No.5, May 10, 2018

  ABSTRACT: Bisphosphonates are among the most frequently used antiresorptive drugs for the management of postmenopausal osteoporosis. We review here two of the commonly used bisphosphonates zoledronate and alendronate.